Biomedical Engineering Reference
In-Depth Information
Rizzo JA (1999) Advertising and competition in the ethical pharmaceutical industry: the case of
antihypertensive drugs. J Law Econ 42(April):89-116
Shankar V (1997) Pioneers' marketing mix reactions to entry in different competitive games struc-
tures: theoretical analysis and empirical illustration. Mark Sci 16(4):271-293
Shankar V, Carpenter GS, Krishnamurthi L (1998) Late mover advantage: how innovative late
entrants outsell pioneers. J Mark Res 35(1):54-70
Shankar V, Carpenter GS, Krishnamurthi L (1999) The advantages of entry in the growth stage of
the product life cycle: an empirical analysis. J Mark Res 36(2):269-276
Skiera B, Albers S (2008) Prioritizing sales force decision areas for productivity improvements
using a core sales response function. J Pers Selling Sales Manag 28(2):145-154
Sridhar S, Mantrala MK, Albers S (2014) Pharmaceutical detailing elasticities, Pharmaceutical
Marketing, Springer's ISQM series (forthcoming)
Srinivasan S, Hanssens DM (2009) Marketing and firm value: metrics, methods, findings, and
future directions. J Mark Res 46(June):293-312
Tull DS, Wood VR, Duhan D, Gillpatrick T, Robertson KR, Helgeson JG (1986) 'Leveraged'
decision making in advertising: the flat maximum principle and its implications. J Mark Res
23(1):25-32
Venkataraman S, Stremersch S (2007) The debate on influencing doctors' decisions: are drug
characteristics the missing link? Manag Sci 53(11):1688-1701
Wagner N, Fischer M (2011) An empirical analysis of the use of rules in the marketing budget allo-
cation process. Working paper, University of Cologne
West D, Crouch GJ (2007) Advertising budgeting practices in Australia and New Zealand.
Australas Mark J 15(3):21-34
Wittink DR (2002) Analysis of ROI for pharmaceutical promotions (ARPP) presentation to
the Association of Medical Publications. http://www.vioworks.com/clients/amp . Accessed 26
Oct 2005
Search WWH ::




Custom Search